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AbstrAct
Background In the pivotal phase III, randomised, double-
blind, placebo-controlled RECOURSE study, treatment with 
trifluridine/tipiracil was well tolerated and associated with 
prolonged progression-free and overall survival in patients 
with metastatic colorectal cancer (mCRC). There was 
no formal analysis of quality of life (QoL) in RECOURSE. 
The aim of the present analysis was to assess proxies 
of QoL during the RECOURSE treatment period, in terms 
of adverse events (AEs) likely to affect QoL and Eastern 
Cooperative Oncology Group performance status (ECOG 
PS).
Patients and methods Enrolled patients had 
documented, previously treated (≥2 prior chemotherapy 
lines) mCRC and an ECOG PS of 0 or 1. Patients received 
best supportive care plus trifluridine/tipiracil 35 mg/
m2 twice daily (n=534) or placebo (n=266) in a 28-day 
cycle. AEs analysed included nausea, vomiting, diarrhoea, 
dysgeusia and fatigue/asthenia. ECOG PS was determined 
at baseline, on day 1 of each treatment cycle, at treatment 
end and 30 days post-treatment discontinuation.
Results AEs that affect QoL were more frequent in 
patients treated with trifluridine/tipiracil than placebo. 
Median treatment duration for patients experiencing at 
least one of these AEs was longer than that observed for 
the overall RECOURSE population (trifluridine/tipiracil: 12 
vs 7 weeks; placebo: 10 vs 6 weeks). Versus placebo, 
the duration of most AEs was longer in trifluridine/
tipiracil recipients; however, all AEs except nausea and 
vomiting occupied a lower proportion of the total treatment 
period. Of the patients who had their PS recorded at 
discontinuation, PS was maintained in 67% and 63% 
of trifluridine/tipiracil and placebo recipients, and 84% 
and 81% of the trifluridine/tipiracil and placebo patients 
remained at a PS of 0 or 1 at discontinuation.
Conclusions Analysis of ECOG PS and AEs thought to 
affect QoL in the RECOURSE patient population suggests 
that trifluridine/tipiracil treatment does not result in a 
deterioration of patient QoL versus placebo.
IntRoduCtIon
Globally, colorectal cancer (CRC) is the third 
most commonly diagnosed cancer (~10% 
of new cases) and is responsible for 8% of 
cancer-related deaths.1 It is now well known 
that quality of life (QoL) is an important issue 
for individuals with cancer, with QoL affected 
by both the disease and therapies used to 
Proxies of quality of life in metastatic 
colorectal cancer: analyses in the 
RECOURSE trial
Eric Van Cutsem,1 Alfredo Falcone,2 Rocio Garcia-Carbonero,3 Yoshito Komatsu,4 
Alessandro Pastorino,5 Marc Peeters,6 Yasuhiro Shimada,7 Kentaro Yamazaki,8 
Takayuki Yoshino,9 Alberto Zaniboni,10 Nadia Amellal,11 Akira Kanehisa,11 
Robert Winkler,12 Lukas Makris,12 Robert J Mayer,13 Atsushi Ohtsu,9 
Josep Tabernero14 
Original research
To cite: Van Cutsem E, 
Falcone A, Garcia-Carbonero R, 
et al. Proxies of quality of 
life in metastatic colorectal 
cancer: analyses in the 
RECOURSE trial. ESMO Open 
2017;2:e000261. doi:10.1136/
esmoopen-2017-000261
Received 18 August 2017
Revised 13 September 2017
Accepted 15 September 2017
For numbered affiliations see 
end of article.
Correspondence to
Dr Eric Van Cutsem;  Eric. 
vancutsem@ uzleuven. be
 ► http:// dx. doi. org/ 10. 1136/ 
esmoopen- 2017- 000284
Key questions
What is already known about this subject?
 ► Quality of life (QoL) is an important issue for 
patients with cancer, since it is impacted by both 
the disease and therapies.
 ► The pivotal RECOURSE trial investigated the efficacy 
and safety of trifluridine/tipiracil in refractory 
metastatic colorectal cancer, but did not include 
QoL questionnaires.
What does this study add?
 ► In patients receiving trifluridine/tipiracil in 
RECOURSE, the occurrence of non-haematological, 
symptomatic adverse events did not result in 
premature treatment discontinuation.
 ► Evaluation of performance status suggests that 
trifluridine/tipiracil preserves QoL versus placebo 
while prolonging overall survival.
 ► Overall, patients treated with trifluridine/tipiracil in 
RECOURSE had preserved performance status in 
84% of cases.
 ► In patients with metastatic colorectal 
cancer receiving trifluridine/tipiracil or placebo in 
RECOURSE, occurrence of adverse events known 
to affect QoL did not result in premature treatment 
discontinuation, and ~70% of patients had 
unchanged performance status, suggesting that 
trifluridine/tipiracil preserves QoL versus placebo 
while prolonging overall survival.
How might this impact on clinical practice?
 ► Our results may raise awareness of the importance 
of taking QoL into consideration in the management 
of patients with colorectal cancer, ultimately 
improving the experience of patients.
 ► Formal assessment of QoL for trifluridine/tipiracil 
is currently underway in observational trials and 
should confirm these results.
Open Access
2 Van Cutsem E, et al. ESMO Open 2017;2:e000261. doi:10.1136/esmoopen-2017-000261
Table 1 Frequency of adverse events experienced during the RECOURSE trial that are likely to affect patient quality of life
Adverse event
Trifluridine/tipiracil (n=533) Placebo (n=265)
Overall 
incidence, % Highest grade
Incidence at 
highest grade, n (%)
Overall 
incidence, % Highest grade
Incidence at 
highest grade, 
n (%)
Nausea 48.4 3 10 (1.9) 23.8 3 3 (1.1)
Vomiting 27.8 3 11 (2.1) 14.3 3 1 (0.4)
Diarrhoea 31.9 4 16 (3.0)* 12.5 3 1 (0.4)
Dysgeusia 6.8 2 3 (0.6) 2.3 2 1 (0.4)
Fatigue 35.3 3 21 (3.9) 23.4 3 15 (5.7)
Asthenia 18.2 3 18 (3.4) 11.3 3 8 (3.0)
*One incidence of grade 4 diarrhoea was observed in trifluridine/tipiracil patients. This number indicates the total number of grade 3 and 4 
diarrhoea events.
Figure 1 Incidence of adverse events by trifluridine/tipiracil treatment cycle.
treat the disease.2–4 In advanced CRC, the main aims of 
treatment are to prolong overall survival (OS) and main-
tain QoL.5
Analysis of QoL assessment in trials of advanced CRC 
has shown that formal assessment of QoL occurred in 
only 27% of phase III trials conducted between 2007 and 
2014.2 Despite this lack of formal analysis, investigation 
of patient symptoms and treatment-related side effects 
remains important in the study of cancer treatments and 
as part of high-quality, patient-centred care. Primarily, 
physician-rated, functional performance status (PS) and 
patient-reported adverse events (AEs) are used to assess 
these treatment effects. Data suggest a significant correla-
tion between PS and patient-reported AEs, both in cancer 
in general and in advanced CRC specifically,6 7 including 
both measures deteriorating concurrently in patients 
with advanced CRC.8
Trifluridine/tipiracil is a combination of the thymi-
dine-based nucleoside analogue trifluridine and the 
thymidine phosphorylase inhibitor tipiracil.9 Trifluri-
dine/tipiracil inhibits thymidylate synthase, disrupting 
DNA synthesis, but its predominant antitumour activity 
results from the incorporation of trifluridine into DNA, 
while tipiracil improves trifluridine bioavailability. Triflu-
ridine/tipiracil is approved in the USA and Europe for 
the treatment of patients with metastatic CRC (mCRC) 
who have been previously treated with currently available 
therapies.10 11 In Japan, it is indicated for the treatment of 
unresectable advanced or recurrent CRC.12 13
The efficacy and safety of trifluridine/tipiracil in patients 
with refractory mCRC have been investigated in the large, 
international RECOURSE (Randomized, Double-Blind, 
Phase 3 Study of TAS-102 plus Best Supportive Care 
(BSC) versus Placebo plus BSC in Patients with Metastatic 
Colorectal Cancer Refractory to Standard Chemothera-
pies) study.14 Median OS in RECOURSE was significantly 
longer in patients treated with trifluridine/tipiracil plus 
BSC versus placebo plus BSC (7.1 vs 5.3 months; HR: 0.68; 
95% CI 0.58 to 0.81; p<0.001). Median progression-free 
survival (PFS) was 2.0 vs 1.7 months (HR: 0.48; 95% CI 
0.41 to 0.57; p<0.001). Common AEs in the RECOURSE 
population included dysgeusia, gastrointestinal AEs 
(nausea and vomiting, diarrhoea) and fatigue/asthenia. 
These AEs are considered likely to affect QoL.15–18
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Figure 2 Median duration of treatment in patients in the RECOURSE trial, stratified by adverse event and in the whole 
population. Pts, patients.
No formal assessment of QoL was undertaken in the 
RECOURSE study. Therefore, the aim of the present 
analysis was to assess AEs likely to affect QoL during the 
course of the trial and Eastern Cooperative Oncology 
Group (ECOG) PS.
MetHods
ReCouRse study design, patient population and treatment 
regimen
Detailed methods of the RECOURSE study have been 
previously published.14 Briefly, RECOURSE was a 
phase III, randomised, double-blind, placebo-controlled 
trial conducted in Japan, Europe, the USA and Australia. 
Patients enrolled were those with documented mCRC 
treated with ≥2 prior lines of standard chemotherapy 
(including anti-epidermal growth factor receptor anti-
body if KRAS wild-type) and an ECOG PS of 0 or 1. All 
patients received BSC and either trifluridine/tipiracil or 
placebo on days 1–5 and 8–12 of each 28-day cycle. Triflu-
ridine/tipiracil was administered at a dose of 35 mg/m2 
twice daily, and three dose reductions (in 5 mg/m2 steps) 
were allowed.
Patients continued study treatment until disease 
progression, death, unacceptable toxicity or patient 
refusal of treatment. Patients were evaluated every 
2 weeks during the treatment period and every 8 weeks 
from treatment cessation until the trial data collection 
cut-off date or death.
Collection of Ae and Ps data
AEs were classified and graded according to the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events, V.4.03.19 PS was evaluated using the 
ECOG score20 at baseline, on day 1 of each treatment 
cycle, at the end of treatment and 30 days after treatment 
discontinuation. Patients who died (PS=5) before treat-
ment discontinuation were not included in the analysis of 
PS at discontinuation.
statistical analysis
AEs for all patients who received at least one dose of study 
drug were summarised using descriptive statistics. The AEs 
included in this analysis were those of high prevalence 
and which were likely to affect QoL: nausea and vomiting, 
diarrhoea, dysgeusia and fatigue/asthenia. ECOG PS at 
treatment discontinuation (ECOG scores of 0–4) was 
compared with PS at baseline in the trifluridine/tipiracil 
and placebo groups using descriptive statistics. Time to 
worsening of ECOG PS was analysed in the intent-to-treat 
population using a two-sided, stratified log-rank test, and 
basing the HR and two-sided 95% CIs on a stratified Cox 
model and associated Kaplan-Meier survival estimates.14 
SAS V.9.1 was used for statistical analyses.
Results
Patient population
RECOURSE enrolled 800 patients, with 534 and 266 
randomised to trifluridine/tipiracil and placebo, respec-
tively.14 The characteristics of the population have been 
previously described14; the main characteristics were as 
follows: median age 63 years, ~61% male and predomi-
nantly white (~57%) or Asian (~34%). ECOG PS was 0 or 
1 in ~55% and ~45% of patients, respectively. The colon 
was the primary site of disease in the majority (~62% of 
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Figure 3 Median duration of adverse events experienced in the RECOURSE trial presented in (A) days and (B) proportion of 
the treatment period.
each group), and most patients (79%) were 18 months 
or more from a diagnosis of first metastases. The mean 
(±SD) duration patients received the study drug was 
12.7±12.0 weeks in the trifluridine/tipiracil group and 
6.8±6.1 weeks in the placebo group.
Aes affecting Qol
Trifluridine/tipiracil patients were more likely to experi-
ence AEs that affect QoL than placebo patients (table 1). 
The overall incidence in the RECOURSE population as 
well as incidence at the highest grade are given for each 
AE likely to affect QoL.
The frequency of AEs was higher during cycle 1 than in 
subsequent cycles for patients treated with trifluridine/
tipiracil (figure 1).
The median treatment duration for all patients in the 
RECOURSE study was 6.7 weeks for the trifluridine/
tipiracil patients and 5.7 weeks for the placebo patients 
(figure 2).14 Notably, the median treatment duration for 
patients experiencing at least one AE likely to affect QoL 
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Table 2 Changes in Eastern Cooperative Oncology 
Group performance status from baseline to treatment 
discontinuation in the RECOURSE trial
Baseline performance status
Trifluridine/tipiracil Placebo
0 (n=278) 1 (n=218) 0 (n=146) 1 (n=117)
Performance status at discontinuation, n (%)
0 180 (65) 8 (4) 86 (60) 4 (3)
1 78 (28) 152 (70) 43 (30) 80 (68)
2 13 (5) 40 (18) 13 (9) 22 (19)
3 6 (2) 17 (8) 4 (3) 8 (7)
4 1 (0.4) 1 (0.5) 0 3 (3)
was longer than that for the whole RECOURSE popula-
tion regardless of treatment allocation (figure 2). Patients 
in the trifluridine/tipiracil group had longer median 
treatment durations than patients in the placebo group.
While most of the AEs experienced by trifluridine/
tipiracil recipients were of longer duration than those 
experienced by placebo recipients (figure 3A), the AEs 
occupied a lower proportion of the total treatment period 
(with the exception of nausea/vomiting) (figure 3B).
Ps at discontinuation
A total of 759 patients had their PS recorded at discon-
tinuation (table 2). Two hundred and seventy-eight and 
146 patients receiving trifluridine/tipiracil and placebo, 
respectively, had a PS of 0 at baseline; 180 (65%) and 86 
(60%) of these patients maintained a PS of 0 at discon-
tinuation. Of the patients receiving trifluridine/tipiracil 
or placebo with a PS of 1 at baseline (n=218 and n=117), 
152 (70%) and 80 (68%) had a PS of 1 at discontinua-
tion; overall, 67% and 63% of trifluridine/tipiracil and 
placebo recipients maintained their PS throughout the 
study. The percentage of patients with a PS of 1 at base-
line who improved to PS 0 at discontinuation was 4% in 
the trifluridine/tipiracil group and 3% in the placebo 
group. Overall, the percentage of patients who were at PS 
0 or 1 at treatment discontinuation was 84% and 81% in 
the trifluridine/tipiracil and placebo groups, respectively. 
In addition, trifluridine/tipiracil significantly delayed the 
median time to an ECOG PS of ≥2 versus placebo (5.7 
vs 4.0 months; HR: 0.66; 95% CI 0.56 to 0.78; p<0.001).14
dIsCussIon
No formal assessment of QoL was performed during the 
RECOURSE study. The present analysis aimed to assess 
the type, timing and duration of AEs known to affect QoL 
and changes in physician-rated functional PS, and use 
these endpoints as surrogates for QoL in the RECOURSE 
population. Evidence suggests that chemotherapy-in-
duced nausea and vomiting, diarrhoea, dysgeusia and 
fatigue/asthenia can have a significant negative impact 
on patients’ QoL.15–18 These AEs were reported more 
frequently in the trifluridine/tipiracil group than in the 
placebo group in RECOURSE. The majority of these 
AEs were mild to moderate in severity, and did not affect 
treatment continuity in a substantial way, being managed 
by dose reductions and/or treatment delays rather than 
hospitalisation.14 21 These AEs are expected in patients 
treated with a thymidine nucleotide analogue,21 are 
predictable and reversible, and were managed appropri-
ately during RECOURSE.
Patients experiencing AEs that affect their QoL might 
be expected to discontinue therapy at a higher rate than 
those who were not; however, patients in RECOURSE who 
experienced these AEs had a longer treatment duration 
than the overall population, and the duration of these 
AEs was generally a lower proportion of the total treat-
ment duration in patients receiving trifluridine/tipiracil 
than in those receiving placebo. These data indicate that 
patients treated with trifluridine/tipiracil remained in 
the study longer than those treated with placebo despite 
a higher likelihood of experiencing more frequent AEs of 
a longer duration that may have affected their QoL.
The original RECOURSE analysis showed that wors-
ening of baseline PS from 0 to 1 to ≥2 was delayed in 
patients receiving trifluridine/tipiracil versus placebo.14 
PS was unchanged in 67% of patients treated with triflu-
ridine/tipiracil, which was a similar proportion to that 
seen in the placebo group (63%), suggesting that PS was 
maintained in patients treated with trifluridine/tipiracil 
despite a higher level of AEs versus placebo.
Assessment of QoL in clinical trials of cancer drugs 
is difficult, being hampered by patient and physician 
subjectivity, complexity and patient adherence.22 Over 
the past 20 years, formal assessment of QoL in advanced 
CRC has decreased such that during 1998–2006, 46% of 
trials formally assessed QoL, while during 2007–2014 this 
decreased to 27% of studies (p=0.04).2 Use of surrogate 
endpoints to assess efficacy in cancer studies can be a risk, 
with evidence suggesting that approvals based on endpoints 
such as tumour shrinkage or PFS can result in agents used 
for treatment that have no benefits on either OS and/or 
QoL.23 In contrast, several studies indicate that PS is related 
to QoL. In a study of patients with pancreatic cancer, those 
with a worse PS self-reported a worse QoL,24 while another 
analysis of patients with metastatic non-small cell lung 
cancer found that higher QoL was significantly associated 
with good PS, and patients who demonstrated a decline 
in QoL also had a decline in PS (p=0.0001 for both).25 A 
systematic review found good correlation between PS and 
patient-reported AEs (including QoL), and suggested 
that assessment of PS and patient-reported AEs may lead 
to more effective patient care.6 Deteriorating PS has been 
associated with a worsening of QoL-related symptoms such 
as fatigue, nausea and diarrhoea.7
The limitations of the current analysis include the 
subjective nature of QoL analysis, and the fact that 
using PS at discontinuation as a surrogate for QoL has 
not been validated and is not formally recognised. The 
strength of the analysis is its consistency. The lack of PS 
deterioration at discontinuation, plus the longer treat-
ment duration in patients experiencing AEs thought to 
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affect QoL, suggests that, in the RECOURSE patients, 
treatment with trifluridine/tipiracil did not affect their 
QoL to the extent where they wished to leave the study. 
In addition, a separate analysis using the Quality-ad-
justed Time WIthout Symptoms of disease or Toxicity 
(QTWIST) method26 has shown an improvement in qual-
ity-adjusted survival in patients treated with trifluridine/
tipiracil versus placebo.27
In conclusion, analysis of PS and AEs thought to 
affect QoL in the RECOURSE patient population suggests 
that trifluridine/tipiracil treatment does not result in 
a deterioration of patient QoL versus placebo while 
prolonging OS. Formal assessment of QoL for trifluri-
dine/tipiracil is currently underway in an observational, 
early-access programme.28
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